Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 601–700 of 10,906
SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
Ao, D., Lan, T., He, X., Liu, J., Chen, L., Baptista‐Hon, D. T., Zhang, K., & Wei, X. (2022) · MedComm · doi:10.1002/mco2.126 · Cited by 129
Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021) · Vaccines · doi:10.3390/vaccines9040390 · Cited by 147
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 122
Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., Breeher, L., Binnicker, M., & Berbari, E. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab229 · Cited by 120
“These results are consistent with previously published data showing a reduction in asymptomatic infection following vaccination with an mRNA vaccine, even after 1 dose [3].”
InfluentialKing, R. G., Silva-Sánchez, A., Peel, J. N., Botta, D., Dickson, A. M., Pinto, A. K., Meza‐Perez, S., Allie, S. R., Schultz, M. D., Liu, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9080881 · Cited by 141
Friedman, M., Curtis, J. R., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221244 · Cited by 135
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz‐Foumani, R., Kolahi, A., Singh, K., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2318 · Cited by 122
Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection
Cheng, F., Huynh, T. K., Yang, C., Hu, D.-W., Shen, Y., Tu, C., Wu, Y., Tang, C., Huang, W., Chen, Y., et al. (2021) · Nutrients · doi:10.3390/nu13082800 · Cited by 134
Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 127
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
Samanovic, M. I., Cornelius, A. R., Gray-Gaillard, S. L., Allen, J. R., Karmacharya, T., Wilson, J. P., Hyman, S. W., Tuen, M., Koralov, S. B., Mulligan, M. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8961 · Cited by 117
Hollow Nanomaterials in Advanced Drug Delivery Systems: From Single‐ to Multiple Shells
Li, Z., Xu, K., Qin, L., Zhao, D., Yang, N., Wang, D., & Yang, Y. (2022) · Advanced Materials · doi:10.1002/adma.202203890 · Cited by 139
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older
Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y.-J., Lewin, B., & Lee, M.-S. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5511 · Cited by 117
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni, M., Casettari, L., & Illum, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120686 · Cited by 128
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
Chiu, N., Chi, H., Tu, Y., Huang, Y.-N., Tai, Y., Weng, S.-L., Chang, L., Huang, D. T., Huang, F.-Y., & Lin, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1971522 · Cited by 121
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
Chivukula, S., Plitnik, T., Tibbitts, T., Karve, S., Dias, A., Zhang, D., Goldman, R., Gopani, H., Khanmohammed, A., Sarode, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00420-6 · Cited by 117
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts
Rashedi, R., Samieefar, N., Masoumi, N., Mohseni, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27463 · Cited by 136
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
He, Q., Mao, Q., Zhang, J., Bian, L., Gao, F., Wang, J., Xu, M., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669339 · Cited by 117
Sacco, C., Manso, M. D., Mateo‐Urdiales, A., Rota, M. C., Petrone, D., Riccardo, F., Bella, A., Siddu, A., Battilomo, S., Proietti, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01185-0 · Cited by 121
Yang, Z., Liu, Y., Zhao, K., Jing, W., Gao, L., Dong, X., Wang, Y., Han, M., Shi, C., Tang, C., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.021 · Cited by 133
Krammer, F., Srivastava, K., the PARIS team, & Simon, V. (2021) · doi:10.1101/2021.01.29.21250653 · Cited by 116
COVID-19 vaccines and kidney disease
Windpessl, M., Bruchfeld, A. N., Anders, H., Kramer, H., Waldman, M. A., Rénia, L., Ng, L. F. P., Xing, Z., & Kronbichler, A. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00406-6 · Cited by 120
Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals
(2021) · doi:10.1101/2021.02.16.21251535 · Cited by 335
Occurrence of severe COVID-19 in vaccinated transplant patients
Caillard, S., Chavarot, N., Bertrand, D., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.011 · Cited by 116
Hildreth, J. E. K., & Alcendor, D. J. (2021) · Vaccines · doi:10.3390/vaccines9050489 · Cited by 130
Vaccination in patients with kidney failure: lessons from COVID-19
Babel, N., Hugo, C., & Westhoff, T. H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00617-5 · Cited by 128
Ciabattini, A., Pastore, G., Fiorino, F., Polvere, J., Lucchesi, S., Pettini, E., Auddino, S., Rancan, I., Durante, M., Miscia, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740708 · Cited by 121
Gushchin, V. А., Dolzhikova, I. V., Shchetinin, A. M., Odintsova, A. S., Siniavin, A. E., Nikiforova, M. A., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Burgasova, O., et al. (2021) · Vaccines · doi:10.3390/vaccines9070779 · Cited by 121
Rahman, M. M., Masum, M. H. U., Wajed, S., & Talukder, A. (2022) · VirusDisease · doi:10.1007/s13337-022-00755-1 · Cited by 127
(2021) · doi:10.1016/j.vaccine.2021.04.002 · Cited by 101
Lee, I. T., Nachbagauer, R., Ensz, D. J., Schwartz, H., Carmona, L., Schaefers, K., Avanesov, A. S., Stadlbauer, D., Henry, C., Chen, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39376-7 · Cited by 129
Self-citationLevi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149154 · Cited by 113
Development of mRNA Vaccines: Scientific and Regulatory Issues
Knezevic, I., Liu, M. A., Peden, K., Zhou, T., & Kang, H.-N. (2021) · Vaccines · doi:10.3390/vaccines9020081 · Cited by 114
“Two mRNA vaccines have demonstrated around 95% efficacy in Phase 3 clinical trials [5,6] and have recently been approved for emergency use by national regulatory authorities in some countries to combat the pandemic [7,8].”
BackgroundWaning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., & Bertollini, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119432 · Cited by 114
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
Almehdi, A. M., Khoder, G., Alchakee, A., Alsayyid, A. T., Sarg, N. H., & Soliman, S. S. M. (2021) · Infection · doi:10.1007/s15010-021-01677-8 · Cited by 123
Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective
Niebel, D., Novak, N., Wilhelmi, J., Ziob, J., Wilsmann‐Theis, D., Bieber, T. R. M., Wenzel, J., & Braegelmann, C. (2021) · Vaccines · doi:10.3390/vaccines9090944 · Cited by 123
Broseta, J. J., Rodríguez‐Espinosa, D., Rodríguez, N., Mosquera, M., Marcos, M. Á., Egri, N., Pascal, M., Soruco, E., Bedini, J. L., Bayés, B., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.002 · Cited by 118
Vaccinations and Autoimmune Diseases
Olivieri, B., Betterle, C., & Zanoni, G. (2021) · Vaccines · doi:10.3390/vaccines9080815 · Cited by 133
Machine Learning for Designing Next-Generation mRNA Therapeutics
Castillo-Hair, S. M., & Seelig, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00621 · Cited by 113
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 130
Manothummetha, K., Chuleerarux, N., Sanguankeo, A., Kates, O. S., Hirankarn, N., Thongkam, A., Dioverti, M. V., Torvorapanit, P., Langsiri, N., Worasilchai, N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6822 · Cited by 120
Connolly, C. M., Ruddy, J. A., Boyarsky, B. J., Barbur, I., Werbel, W. A., Geetha, D., Garonzik‐Wang, J., Segev, D. L., Christopher‐Stine, L., & Paik, J. J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41924 · Cited by 121
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
Choi, A., Koch, M., Wu, K., Dixon, G., Oestreicher, J., Legault, H., Stewart-Jones, G. B. E., Colpitts, T., Pajon, R., Bennett, H., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01313-21 · Cited by 113
Self-citationMcIntosh, L., Bankier, A. A., Vijayaraghavan, G. R., Licho, R., & Rosen, M. P. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25728 · Cited by 114
SARS-CoV-2 vaccines: a triumph of science and collaboration
Golob, J. L., Lugogo, N. L., Lauring, A. S., & Lok, A. S.-F. (2021) · JCI Insight · doi:10.1172/jci.insight.149187 · Cited by 121
Renoud, L., Khouri, C., Revol, B., Lepelley, M., Perez, J., Roustit, M., & Cracowski, J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2219 · Cited by 122
Goldman, J. D., Robinson, P. C., Uldrick, T. S., & Ljungman, P. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002630 · Cited by 122
SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting
Butt, A. A., Omer, S. B., Yan, P., Shaikh, O. S., & Mayr, F. B. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1577 · Cited by 109
(2021) · doi:10.1371/journal.pmed.1003769 · Cited by 111
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 144
Regulating trained immunity with nanomedicine
van Leent, M. M. T., Priem, B., Schrijver, D. P., de Dreu, A., Hofstraat, S. R. J., Zwolsman, R. C., Beldman, T. J., Netea, M. G., & Mulder, W. J. M. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00413-w · Cited by 122
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 124
O’Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K.-C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., et al. (2022) · JAMA · doi:10.1001/jama.2021.24939 · Cited by 124
Self-citationA Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility
Wesselink, A. K., Hatch, E. E., Rothman, K. J., Wang, T. R., Willis, M. D., Yland, J. J., Crowe, H. M., Geller, R. J., Willis, S. K., Perkins, R. B., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac011 · Cited by 120
Lam, K., Leung, A., Martin, A., Wood, M., Schreiner, P., Palmer, L., Daly, O. M., Zhao, W., McClintock, K., & Heyes, J. A. (2023) · Advanced Materials · doi:10.1002/adma.202209624 · Cited by 145
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 112
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD
Carr, E. J., Kronbichler, A., Graham-Brown, M. P. M., Abra, G. E., Argyropoulos, C., Harper, L., Lerma, E. V., Suri, R. S., Topf, J. M., Willicombe, M. K., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.027 · Cited by 129
Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 117
Self-citationOral mRNA delivery using capsule-mediated gastrointestinal tissue injections
Abramson, A., Kirtane, A. R., Shi, Y., Zhong, G., Collins, J. E., Tamang, S. M., Ishida, K., Hayward, A. M., Wainer, J., Rajesh, N. U., et al. (2022) · Matter · doi:10.1016/j.matt.2021.12.022 · Cited by 111
Future considerations for the mRNA-lipid nanoparticle vaccine platform
Igyártó, B. Z., Jacobsen, S., & Ndeupen, S. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.03.008 · Cited by 110
Puig‐Domingo, M., Marazuela, M., Yıldız, B. O., & Giustina, A. (2021) · Endocrine · doi:10.1007/s12020-021-02734-w · Cited by 120
COVID-19 Vaccine Booster: To Boost or Not to Boost
Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 112
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S.-S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 109
Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants
Sah, P., VILCHES, T. N., Moghadas, S. M., Fitzpatrick, M. C., Singer, B. H., Hotez, P. J., & Galvani, A. P. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100865 · Cited by 112
Izikson, R., Brune, D., Bolduc, J.-S., Bourron, P., Fournier, M., Moore, T. M., Pandey, A., Perez, L., Sater, N., Shrestha, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00557-9 · Cited by 112
Song, Q., Bates, B. A., Shao, Y. R., Hsu, F., Liu, F., Madhira, V., Mitra, A., Bergquist, T., Kavuluru, R., Li, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02419 · Cited by 114
Advances in Infectious Disease Vaccine Adjuvants
Fan, J., Jin, S., Gilmartin, L., Tóth, I., Hussein, W. M., & Stephenson, R. J. (2022) · Vaccines · doi:10.3390/vaccines10071120 · Cited by 133
Gadani, S. P., Reyes-Mantilla, M. I., Jank, L., Harris, S., Douglas, M., Smith, M. D., Calabresi, P. A., Mowry, E. M., Fitzgerald, K. C., & Bhargava, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103636 · Cited by 104
Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?
Das, B. B., Moskowitz, W. B., Taylor, M., & Palmer, A. (2021) · Children · doi:10.3390/children8070607 · Cited by 115
Disanto, G., Sacco, R., Bernasconi, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3609 · Cited by 109
Fusco, M. D., Lin, J., Vaghela, S., Lingohr-Smith, M., Nguyen, J. L., Sforzolini, T. S., Judy, J., Cane, A. D., & Moran, M. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2035222 · Cited by 116
Lundberg, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023) · BMJ · doi:10.1136/bmj-2023-076990 · Cited by 121
The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
Jabłońska, K., Aballéa, S., & Toumi, M. (2021) · Public Health · doi:10.1016/j.puhe.2021.07.037 · Cited by 116
Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.08.21259776 · Cited by 108
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
(2021) · doi:10.1101/2021.08.25.21262584 · Cited by 831
Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers
Yin, D., Zhong, Y., Ling, S., Lu, S., Wang, X., Jiang, Z., Wang, J., Dai, Y., Tian, X., Huang, Q., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01208-4 · Cited by 127
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Müller, M. A., Richter, A. M., Schmandke, A., Schmidt, M. L., Schmidt, T. H., de Vries, F. M., Drosten, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22351-5 · Cited by 115
Karaba, A. H., Zhu, X., Liang, T., Wang, K., Rittenhouse, A. G., Akinde, O., Eby, Y. J., Ruff, J. E., Blankson, J. N., Abedon, A. T., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16933 · Cited by 115
COVID-19 Vaccine Hesitancy among French People Living with HIV
Vallée, A., Fourn, E., Majerholc, C., Touche, P., & Zucman, D. (2021) · Vaccines · doi:10.3390/vaccines9040302 · Cited by 119
Kacherovsky, N. A., Yang, L. F., Dang, H. V., Cheng, E. L., Cardle, I. I., Walls, A. C., McCallum, M., Sellers, D. L., DiMaio, F., Salipante, S. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107730 · Cited by 113
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
Green, M. S., Peer, V., Magid, A., HaGani, N., Anis, E., & Nitzan, D. (2022) · Vaccines · doi:10.3390/vaccines10020233 · Cited by 118
Recent developments in the immunopathology of COVID ‐19
Zhang, H., Sun, Y., Wang, Y., Yazıcı, D., Azkur, D., Öğülür, İ., Azkur, A. K., Yang, Z., Chen, X., Zhang, A., et al. (2022) · Allergy · doi:10.1111/all.15593 · Cited by 125
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 137
Bravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsaat, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00055-1 · Cited by 106
Bell’s palsy following COVID-19 vaccination
Colella, G., Orlandi, M., & Cirillo, N. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10462-4 · Cited by 105
The COVID-19 pandemic: viral variants and vaccine efficacy
Ciotti, M., Ciccozzi, M., Pieri, M., & Bernardini, S. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1979462 · Cited by 118
Bonilla, H. F., Peluso, M. J., Rodgers, K. E., Aberg, J. A., Patterson, T. F., Tamburro, R. F., Baizer, L., Goldman, J. D., Rouphael, N., Deitchman, A. N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129459 · Cited by 113
Self-citationBrockman, M. A., Mwimanzi, F. M., Lapointe, H. R., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L. Y., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab592 · Cited by 111
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
Vijenthira, A., Gong, I. Y., Betschel, S., Cheung, M. C., & Hicks, L. K. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004629 · Cited by 123
The potential neurological effect of the COVID‐19 vaccines: A review
Lu, L., Xiong, W., Mu, J., Zhang, Q., Zhang, H., Zou, L., Li, W., He, L., Sander, J. W. A. S., & Zhou, D. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13417 · Cited by 111
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 115
Kamiya, M., Matsumoto, M., Yamashita, K., Izumi, T., Kawaguchi, M., Mizukami, S., Tsurumaru, M., Mukai, H., & Kawakami, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112357 · Cited by 123
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 120
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 129
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 114
Self-citationAnsari, S., Hays, J. P., Kemp, A. H., Okechukwu, R. C., Murugaiyan, J., Ekwanzala, M. D., Alvarez, M. J. R., Satyaseela, M. P., Iwu, C. D., Ballesté‐Delpierre, C., et al. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab038 · Cited by 128
mRNA Covid-19 vaccines in pregnancy: A systematic review
Pratama, N. R., Wafa, I. A., Budi, D. S., Putra, M., Wardhana, M. P., & Wungu, C. D. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261350 · Cited by 107
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury, J., Najjar‐Debbiny, R., Hanna, A., Jabbour, A. R., Ahmad, Y. A., Saffuri, A., Abu-Sinni, M., Shkeiri, R., Elemy, A., & Hakim, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.038 · Cited by 111
Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 116
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.